4119.TW

SCI Pharmtech, Inc. [4119.TW] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

4119.TW Stock Summary

Earnings have grown 33.83% per last year.

The Moving Average Convergence Divergence (MACD) for 4119.TW recently turned positive (within last 10 days).

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 quarters (Quarter statements)

4119.TW has less than 1 year of cash runway

Top 10 Correlated ETFs

4119.TW

Top 10 Correlated Stocks

4119.TW

In the News

4119.TW Financial details

Company Rating

Neutral

Market Cap

10.58B

Income

294.72M

Revenue

1.2B

Book val./share

42.67

Cash/share

8.63

Dividend

0.25

Dividend %

0.26%

Employees

202

Optionable

Shortable

Yes

Earnings

10 May 2024

P/E

27.76

Forward P/E

PEG

-23.79

P/S

9.89

P/B

2.53

P/C

10.01

P/FCF

-13.97

Quick Ratio

0.91

Current Ratio

1.99

Debt / Equity

0.2

LT Debt / Equity

0.17

EPS (TTM)

2.5

EPS next Y

EPS next Q

EPS this Y

-4.59%

EPS next Y

EPS next 5Y

EPS last 5Y

-12.42%

Revenue last 5Y

-12.56%

Revenue Q/Q

13.02%

EPS Q/Q

-109.44%

SMA20

SMA50

-7.37%

SMA100

-1.12%

Inst Own

Inst Trans

ROA

ROE

10%

ROC

0.1%

Gross Margin

32%

Oper. Margin

42%

Profit Margin

33%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

86.6-117.69871

52W High

-26.15%

52W Low

+0.47%

RSI

Rel Volume

1.65

Avg Volume

256.32K

Volume

424.19K

Perf Week

-3.46%

Perf Month

-4.95%

Perf Quarter

-4.42%

Perf Half Y

-6.19%

Beta

-0.156

Volatility

0.78%, 0.92%

Prev Close

-2.15%

Price

86.4

Change

-2.37%

4119.TW Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	21.61	24.67	7.93	8.25	11.02
Net income per share	5.24	3.3	0.51	2.83	2.7
Operating cash flow per share	7.26	8.91	2.57	2.72	1.97
Free cash flow per share	5.39	6.92	-4.54	-7.99	-7.44
Cash per share	9.35	5.81	6.35	2.43	9.43
Book value per share	31.88	30.48	30.47	33.3	46.66
Tangible book value per share	31.44	30.1	29.91	32.8	46.66
Share holders equity per share	31.88	30.48	30.47	33.3	46.66
Interest debt per share	0.03	0.02	0.02	5.01	9.59
Market cap	8.8B	6.78B	8.14B	9.45B	10.75B
Enterprise value	8.25B	6.15B	7.81B	9.83B	10.85B
P/E ratio	15.41	18.83	146.13	30.59	36.46
Price to sales ratio	3.74	2.52	9.42	10.5	8.92
POCF ratio	11.12	6.98	29.04	31.85	49.8
PFCF ratio	14.99	9	-16.45	-10.85	-13.21
P/B Ratio	2.53	2.04	2.45	2.6	2.11
PTB ratio	2.53	2.04	2.45	2.6	2.11
EV to sales	3.5	2.29	9.04	10.92	9.01
Enterprise value over EBITDA	9.8	10.2	61.48	19.85	20.93
EV to operating cash flow	10.42	6.33	27.86	33.13	50.26
EV to free cash flow	14.05	8.16	-15.78	-11.28	-13.33
Earnings yield	0.06	0.05	0.01	0.03	0.03
Free cash flow yield	0.07	0.11	-0.06	-0.09	-0.08
Debt to equity	0	0	0	0.15	0.2
Debt to assets	0	0	0	0.11	0.16
Net debt to EBITDA	-0.65	-1.05	-2.6	0.76	0.19
Current ratio	3.31	1.71	1.87	1.35	3.43
Interest coverage	13.56K	10.92K	1.54K	377.14	59.29
Income quality	1.11	2.13	4.28	0.76	0.59
Dividend Yield	0.04	0.07	0	0	0
Payout ratio	0.58	1.28	0.71	0	0.08
Sales general and administrative to revenue	0.04	0.03	0.06	0.09	0.07
Research and developement to revenue	0.02	0.02	0.04	0.04	0.04
Intangibles to total assets	0.01	0.01	0.01	0.01	0.01
Capex to operating cash flow	-0.26	-0.22	-2.77	-3.94	-4.77
Capex to revenue	-0.09	-0.08	-0.9	-1.3	-0.85
Capex to depreciation	-1.5	-1.63	-12.16	-12.89	-7.08
Stock based compensation to revenue	0	0	0	0	0.02
Graham number	61.3	47.6	18.72	46.07	53.2
ROIC	0.16	0.11	0.02	0.08	0.05
Return on tangible assets	0.14	0.08	0.01	0.06	0.04
Graham Net	8.63	-1.57	2.13	-6.03	-0.59
Working capital	1.35B	796.6M	649.37M	272.08M	1.38B
Tangible asset value	3.43B	3.28B	3.26B	3.57B	5.05B
Net current asset value	1.33B	671.1M	528.05M	-288.92M	362.45M
Invested capital	0	0	0	0.15	0.2
Average receivables	371.66M	345.08M	343.16M	276.61M	256.09M
Average payables	91.73M	87.59M	57.33M	41.21M	46.44M
Average inventory	515.08M	453.98M	337.53M	403.81M	521.48M
Days sales outstanding	54.6	45.84	147.21	83.03	93.21
Days payables outstanding	24.24	20.86	18.79	29.17	18.92
Days of inventory on hand	135.48	98.26	163.65	307.94	226.37
Receivables turnover	6.68	7.96	2.48	4.4	3.92
Payables turnover	15.06	17.49	19.42	12.51	19.3
Inventory turnover	2.69	3.71	2.23	1.19	1.61
ROE	0.16	0.11	0.02	0.09	0.06
Capex per share	-1.88	-2	-7.11	-10.71	-9.42

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	2.07	3.14	2.55	2.36	2.44
Net income per share	0.72	0.58	1.63	0.32	-0.03
Operating cash flow per share	0.52	-1.37	2.21	0.6	0.23
Free cash flow per share	-2.99	-4.15	1.83	-2.31	-2.79
Cash per share	2.43	1.81	1.9	2.12	8.63
Book value per share	33.3	33.85	33.51	37.81	42.67
Tangible book value per share	32.8	33.36	33.1	37.81	42.67
Share holders equity per share	33.3	33.85	33.51	37.81	42.67
Interest debt per share	5.01	8.53	5.72	8.08	8.74
Market cap	9.45B	11.48B	12.92B	10.47B	11.75B
Enterprise value	9.83B	12.31B	13.47B	11.21B	11.85B
P/E ratio	30.03	45.24	16.18	74.01	-813.33
Price to sales ratio	41.84	33.59	41.25	40.62	40.31
POCF ratio	165.28	-77.16	47.58	160.8	420
PFCF ratio	-29.02	-25.39	57.56	-41.55	-35.2
P/B Ratio	2.6	3.11	3.14	2.54	2.3
PTB ratio	2.6	3.11	3.14	2.54	2.3
EV to sales	43.52	36.01	43.02	43.49	40.66
Enterprise value over EBITDA	76.01	111.92	46.42	139.93	312.55
EV to operating cash flow	171.91	-82.73	49.63	172.17	423.59
EV to free cash flow	-30.18	-27.22	60.04	-44.49	-35.5
Earnings yield	0.01	0.01	0.02	0	0
Free cash flow yield	-0.03	-0.04	0.02	-0.02	-0.03
Debt to equity	0.15	0.25	0.17	0.21	0.2
Debt to assets	0.11	0.18	0.13	0.16	0.16
Net debt to EBITDA	2.93	7.53	1.91	9.24	2.65
Current ratio	1.35	1.15	1.86	1.99	3.43
Interest coverage	229.4	45.8	137.33	37.32	-4.57
Income quality	0.59	-1.89	1.08	1.47	-2.72
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0.67	0
Sales general and administrative to revenue	0.09	0.05	0.05	0.06	0.11
Research and developement to revenue	0.05	0.03	0.04	0.05	0.04
Intangibles to total assets	0.01	0.01	0.01	0.01	0.01
Capex to operating cash flow	-6.7	2.04	-0.17	-4.87	-12.93
Capex to revenue	-1.7	-0.89	-0.15	-1.23	-1.24
Capex to depreciation	-13.84	-9.53	-1.44	-8.81	-8.06
Stock based compensation to revenue	0	0	0	0	0
Graham number	23.25	21.05	35.03	16.6	5.39
ROIC	0.02	0.01	0.04	0.01	0
Return on tangible assets	0.02	0.01	0.04	0.01	0
Graham Net	-6.03	-8.06	-5.01	-6.66	-0.54
Working capital	272.08M	137.49M	505.77M	553.33M	1.38B
Tangible asset value	3.57B	3.64B	4.06B	4.08B	5.05B
Net current asset value	-288.92M	-493.49M	-215.73M	-315.26M	362.45M
Invested capital	0.15	0.25	0.17	0.21	0.2
Average receivables	216.02M	229.67M	270.88M	282.96M	293.17M
Average payables	44.38M	47.73M	41.75M	34.18M	37.96M
Average inventory	470.62M	517.24M	504.25M	503.26M	524.31M
Days sales outstanding	81.59	67.06	82.52	97.32	94.97
Days payables outstanding	30.64	19.26	14.15	16.04	17.78
Days of inventory on hand	323.44	214.36	188	262.9	212.74
Receivables turnover	1.1	1.34	1.09	0.92	0.95
Payables turnover	2.94	4.67	6.36	5.61	5.06
Inventory turnover	0.28	0.42	0.48	0.34	0.42
ROE	0.02	0.02	0.05	0.01	0
Capex per share	-3.51	-2.78	-0.38	-2.9	-3.03

4119.TW Dividend History

4119.TW Frequently Asked Questions

What is SCI Pharmtech, Inc. stock symbol ?

SCI Pharmtech, Inc. is a TW stock and trading under the symbol 4119.TW

What is SCI Pharmtech, Inc. stock quote today ?

SCI Pharmtech, Inc. stock price is $86.4 today.

Is SCI Pharmtech, Inc. stock public?

Yes, SCI Pharmtech, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 256.32K
Market Capitalization 10.58B
Employee 202
CEO Mr. Wen-Chih Chou
Headquarters Taoyuan City,TW
IPO Date 2004-01-07
Website https://www.sci-pharmtech.com.tw

SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and specialty chemicals. Its active pharmaceutical ingredients include Articaine HCl, Atomoxetine HCl, Bisoprolol Fumarate, Brinzolamide, Divalproex Sodium, Duloxetine HCl, Hydroxychloroquine sulfate, Loxoprofen Sodium, Methylphenidate HCl, Pentobarbital Sodium, Probucol, Propafenone HCl, Sodium Valproate, Thiopental, Valproic Acid, Adenine, Cannabidiol, and Dexmethylphenidate HCl. The company's intermediate products comprise Azetidin-3-ol hydrogenchloride, Diethyl Isobutyl Malonate, Diethyl dipropylmalonate, Diethyl ethyl(1-methylbutyl)malonate, Pyrogallolaldehyde, Benzhydrylamine, 1-Benzhydrylazetidin-3-ol, 1-(2-Hydroxyphenyl)-3-phenylpropan-1-one, N-Methyl-4-piperidinol, Ritalinic acid, d-Ritalinic acid HCl, (1R, 2S)-1 Phenyl-2-(pyrrolldin-1-yl)propan-1-ol HCl, and (1R, 2S)-1 Phenyl-2-(pyrrolldin-1-yl)propan-1-ol. Its intermediate products also consists of (S)-3-(methylmino)-1-(2-thi-enyl)propan-1-ol, (R)-3-(Methylamino)-1-phenylpropanol, (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol, Menthadienol, 5-pentylbenzene-1,3-diol Olivetol, Methyl 2,4-dihydroxy-6-pentylbenzoate, and Ethyl 2,4-dihydroxy-6-pentylbenzoate Ethyl Olivetolate. The company also provides custom manufacturing services. It sells its products in Italy, China, the United States, Germany, Taiwan, Switzerland, Spain, Japan, Netherlands, and internationally. The company was incorporated in 1987 and is based in Taoyuan City, Taiwan.